MedTrace Logo

Effectiveness of Colchicine Among Patients With COVID-19 Infection

NCT04867226 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-06-22

No results posted yet for this study

Summary

In November 2019, there were a lot of cases of an acute respiratory illness (then named at February 11th as COVID\_19) which first case was reported in Wuhan, China,The SARS COV-2 had been spread in a fast way to involve whole world, As it's obvious that Colchicine is a drug that is most commonly and widely used to treat and prevent acute attacks of Gout, other crystal induced arthropathy,colchicine has important role in inhibiting activation of NLRP3 inflammasome these lead to decrease cytokine production , aim of study To evaluate whether colchicine is effective in the treatment of COVID-19 cases. And to measure the effectiveness of colchicine in alleviating and controlling pulmonary and extra pulmonary complications of COVID-19

Conditions

  • Coronavirus Infection

Interventions

DRUG

Colchicine 0.5 MG

participant will be given a Colchicine regimen in a dose of 0.5mg twice daily for 14 days or until symptoms subsides,those with low body weight and develop side effect like diarrhea and vomiting dose will be reduced and supportive treatment will be given .

DRUG

usual care treatment

control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • Dashty Albustany, MBChB.FRCP · assistant professor in medicine,consultant Rheumatologist

  • Aryan MF Jalal · M.B.CH.B, doctor Rheumatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-08
Primary Completion
2021-06-18
Completion
2021-06-18

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04867226 on ClinicalTrials.gov